EUVIMEDEUVIMED entdecken
Crossref

Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?

Ali Darvishi, Ramin Abdi Dezfouli, Aliakbar Fazaeli, Rajabali Daroudi, Narges Zandieh

Expert Review of Pharmacoeconomics & Outcomes Research · 2023

DOI: 10.1080/14737167.2023.2263167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2023. Verfasst von Ali Darvishi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: This study evaluates the cost-effectiveness of Palbociclib in the second-line treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) in Iran. METHODS: The present economic evaluation used a partitioned survival model (PSM). This model compares lifetime costs and disease outcomes among groups receiving different medication combinations containing Palbociclib, Fulvestrant, Everolimus, Ribociclib, and Abemaciclib as the second-line therapy for HR+/HER2- MBC. The model was conducted from Iran's healthcare perspective, structured with 1-month cycles, and the evaluation time horizon in the base analysis was set to 180 cycles (15 years). Transition probabilities were extracted using the survival curves. The cost information was extracted based on the year 2020. The Quality Adjusted Life Years (QALY) was considered the final outcome unit, and the cost-effectiveness of different combinations is calculated as cost per QALY. The annual discount rate of 5% was considered for costs and QALYs. Two times Iran's GDP per capita (800,000,000 IRR = US$5934) was used as the threshold. Finally, due to the uncertainty of some parameters, deterministic and probabilistic sensitivity analyses were carried out. RESULTS: The base case results showed that the highest cost was for the 'Ribociclib+ Fulvestrant' combination (US$89,629.56), and the lowest price was for the 'Iranian Everolimus + Fulvestrant' combination (US$10,740.09). 'Palbociclib + Fulvestrant' brings about the highest value of 1.456 incremental QALYs compared to other strategies. Finally, the 'Iranian Palbociclib + Fulvestrant' was the cost-effective combination, with an incremental cost-effectiveness ratio (ICER) of US$4,201 compared to other strategies. The base case results were supported by the probabilistic sensitivity analysis. Deterministic sensitivity analysis showed that the cost of Iranian Palbociclib has a threshold of US$582.99. CONCLUSIONS: The 'Iranian Palbociclib + Fulvestrant' combination was cost-effective in second-line therapy for HR+ HER2- MBC in Iran.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleIranFulvestrantEverolimusCost-Benefit AnalysisAntineoplastic Combined Chemotherapy ProtocolsAminopyridinesPurinesPiperazinesPyridines

Stichwörter der Autor:innen

Economic evaluationHR+ HER2-Palbociclibcost-effectivenessmetastatic breast cancersecond-line treatment

Substanzen

FulvestrantEverolimusribociclibAminopyridinesPurinespalbociclibPiperazinesPyridines

Autor:innen und Institutionen

  • Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • National Center for Health Insurance Research, Tehran, Iran.
  • Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Förderung

  • Ministry of Health

Zitieren

APA

Darvishi, A., Abdi Dezfouli, R., Fazaeli, A., Daroudi, R., & Zandieh, N. (2023). Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2263167

Vancouver

Darvishi A, Abdi Dezfouli R, Fazaeli A, Daroudi R, Zandieh N. Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?. Expert Review of Pharmacoeconomics & Outcomes Research. 2023. doi:10.1080/14737167.2023.2263167

BibTeX
@article{Darvishi2023,
  author = {Darvishi, Ali and Abdi Dezfouli, Ramin and Fazaeli, Aliakbar and Daroudi, Rajabali and Zandieh, Narges},
  title = {Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2023},
  doi = {10.1080/14737167.2023.2263167}
}
Kostenlos starten →